Structure Therapeutics, Inc. (GPCR)
45.91
-1.46
(-3.08%)
USD |
NASDAQ |
Aug 31, 16:00
46.00
+0.09
(+0.20%)
After-Hours: 06:47
Structure Therapeutics Cash from Investing (Quarterly) : 75.10M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 75.10M |
| March 31, 2026 | -498.43M |
| December 31, 2025 | 56.31M |
| September 30, 2025 | -49.46M |
| June 30, 2025 | 49.10M |
| March 31, 2025 | 34.08M |
| December 31, 2024 | 33.49M |
| September 30, 2024 | -189.76M |
| June 30, 2024 | -204.24M |
| Date | Value |
|---|---|
| March 31, 2024 | 1.416M |
| December 31, 2023 | -180.89M |
| September 30, 2023 | 29.79M |
| June 30, 2023 | -68.09M |
| March 31, 2023 | -48.92M |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | -15.95M |
| March 31, 2022 | -39.77M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly & Co. | -15.40B |
| Novo Nordisk A/S | -2.009B |
| Pfizer Inc. | 2.106B |
| Johnson & Johnson | -1.11B |
| Zevra Therapeutics, Inc. | 31.45M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -120.38M |
| Cash from Financing (Quarterly) | 2.091M |
| Free Cash Flow | -225.05M |
| Free Cash Flow Per Share (Quarterly) | -1.656 |
| Free Cash Flow to Equity (Quarterly) | -120.77M |
| Free Cash Flow to Firm (Quarterly) | -120.34M |
| Free Cash Flow Yield | -7.46% |